Streetbeat News

SNES

SenesTech, Inc.

https://www.senestech.com

Industry

Chemicals - Specialty

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

Open

2.43

Mkt cap

2.3M

Volume

231K

High

2.43

P/E Ratio

0.02

52-wk high

9.80

Low

2.12

Div yield

N/A

52-wk low

1.90

SenesTech, Inc. has entered into an exclusive distribution agreement with Fruit Tree Limited for its Evolve Soft Bait product in Hong Kong and Macau. The agreement includes an initial order for the product, which is designed for rodent control.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:01 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Virpax Pharmaceuticals (VRPX) saw a 57.8% increase, while Verrica Pharmaceuticals (VRCA) rose by 51.06%. ASLAN Pharma (ASLN), Biophytis (BPTS), Context Therapeutics (CNTX), and Immix Biopharma (IMMX) also saw gains. Conversely, Aadi Bioscience (AADI), Aileron Therapeutics (ALRN), Cingulate (CING), Vapotherm (VAPO), SenesTech (SNES), and IN8bio (INAB) experienced declines, with AADI dropping 56.5%.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:31 pm

SenesTech shares have risen following the announcement of receiving 'substantial orders' for its EVOLVE Soft Bait product, indicating strong market demand and potential revenue growth.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:38 pm

SenesTech, Inc. (NASDAQ:SNES) has received substantial orders for its new product, EVOLVE Soft Bait, a non-lethal rodent fertility control solution. Launched in November 2023, EVOLVE has seen strong demand, leading to increased production. The product is seen as an alternative to traditional poisons, with some regions like New England considering bans on second-generation anticoagulants (SGARs) due to environmental concerns.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 2:14 pm

SenesTech, Inc. (NASDAQ:SNES) has announced that its ContraPest products are now registered for sale and use in Puerto Rico. ContraPest is an EPA-registered rat contraceptive that affects both male and female rats and is designed to fit into integrated pest management programs. The company is finalizing plans with a large agricultural firm in Puerto Rico to be its lead customer. SenesTech offers four fertility control products, including the Ultimate Bait System, Isolate Bait System, Elevate Bait System, and Evolve Soft Bait. The registration in Puerto Rico is expected to help combat the significant rat infestation problem on the island, which impacts the grain industry and poses public health risks.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:09 pm

U.S. stocks saw gains with the Dow Jones rising by 0.27%, NASDAQ by 0.12%, and S&P 500 by 0.07%. Consumer discretionary shares led the gains, while health care shares declined. Crude oil surged by 2.1%, and gold also rose. Carbon Revolution, PDD Holdings, and IceCure Medical saw significant stock price increases following positive news. Tharimmune's shares plummeted after pricing a public offering at $1 per share. SenesTech and Cabaletta Bio also experienced sharp declines in their share prices.

Portfolio Pulse from Lisa Levin

November 28, 2023 | 7:57 pm

SenesTech, Inc. (NASDAQ:SNES) shares plummeted by approximately 50% after announcing the pricing of a $5.0 million public offering at $1.30 per share with additional warrants. The stock dropped to $0.9189. Other stocks experienced significant movements, with gainers including IceCure Medical Ltd (ICCM), RedHill Biopharma Ltd. (RDHL), and HNR Acquisition Corp (HNRA), among others. Losers included Tharimmune, Inc. (THAR), Cabaletta Bio, Inc. (CABA), and Acelyrin, Inc. (SLRN), with Tharimmune's shares falling sharply after pricing its public offering at $1 per share.

Portfolio Pulse from Lisa Levin

November 28, 2023 | 7:44 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Redhill Biopharma (RDHL) saw a 62.0% increase, Cardio Diagnostics Hldgs (CDIO) rose by 27.87%, and Heart Test Laboratories (HSCS) increased by 24.98%. Conversely, Tharimmune (THAR) dropped by 71.8%, SenesTech (SNES) fell by 45.22%, and Cabaletta Bio (CABA) declined by 34.44%. Other notable movers included SpringWorks Therapeutics (SWTX), Iterum Therapeutics (ITRM), IMAC Hldgs (BACK), Biodexa Pharmaceuticals (BDRX), Gracell Biotechnologies (GRCL), and Autolus Therapeutics (AUTL).

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 5:31 pm

SenesTech Inc (NASDAQ:SNES) stock plummeted by 36% to $1.18 after announcing a public offering of approximately 3.8 million shares at $1.30 per share, with additional warrants. The offering aims to raise about $5.0 million for general corporate purposes, R&D, and potential acquisitions. The offering is expected to close by November 30, with H.C. Wainwright & Co. as the exclusive placement agent. This follows a brief rise in after-hours trading due to the launch of Evolve Soft Bait at Ace Hardware in California. SNES's 52-week range is $1.75 to $80.98.

Portfolio Pulse from Henry Khederian

November 28, 2023 | 1:43 pm

SenesTech shares have declined following the announcement of a $5 million public offering. The offering is likely dilutive to existing shareholders, causing the stock price to drop.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.